Please assess the completion status of the following clinical trial:

Trial Title: Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any child 2-12 months old seen in the emergency department.~* A clinical bronchiolitis score \> 3 by modified Wood's Clinical Bronchiolitis Score (M-WCBS).~* Diagnostic criteria of bronchiolitis includes tachypnea, cough, prolonged expiratory phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest radiograph. After consenting a patient to the study, respiratory syncytial virus (RSV) infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal secretions.~Exclusion Criteria:~* No child will be excluded based on race or gender~* Patients under the age of 2 months or greater than 12 months~* Patients with cyanotic heart disease~* Patients with lobar pneumonia, defined by results of chest radiographs.~* The presence of interstitial disease or diffuse patchy marking consistent with atelectasis on chest radiographs will not exclude patients.~* Patients with croup.~* Patients with foreign body aspiration.~* Patients with history of cystic fibrosis, bronchopulmonary dysplasia or other chronic lung disease.~* Patients with liver or renal disease.~* Patients with sickle cell anemia.~* Patients requiring mechanical ventilation.~* Patients who develop supraventricular tachycardia secondary to racemic epinephrine administration.~* Patients with tracheomalacia or bronchomalacia.~* Patients who had received bronchodilators within 2 hours of initiation of the study.~* Patients who had received systemic corticosteroids within 72 hours of enrollment~* Patients who suffered from persistent airway hyperreactivity in the 3 months before the study.~* Patients who do not tolerate the nasal cannulae for 45 out of 60 minutes.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- heliox (Type: OTHER): heliox-driven nebulizations for children with moderate to severe bronchiolitis
- oxygen (Type: OTHER): oxygen-driven nebulizations for children with moderate to severe bronchiolitis

Based on this trial design, predict the completion outcome and termination type (if applicable).